Mechanistic target of rapamycin (MTOR) plays a critical role in the regulation of cell growth and in the response to energy state changes. Drugs inhibiting MTOR are increasingly used in antineoplastic therapies. Myocardial MTOR activity changes during hypertrophy and heart failure (HF). However, whether MTOR exerts a positive or a negative effect on myocardial function remains to be fully elucidated. Here, we show that ablation of Mtor in the adult mouse myocardium results in a fatal, dilated cardiomyopathy that is characterized by apoptosis, autophagy, altered mitochondrial structure, and accumulation of eukaryotic translation initiation factor 4E–binding protein 1 (4E-BP1). 4E-BP1 is an MTOR-containing multiprotein complex-1 (MTORC1) substrate that inhibits translation initiation. When subjected to pressure overload, Mtor-ablated mice demonstrated an impaired hypertrophic response and accelerated HF progression. When the gene encoding 4E-BP1 was ablated together with Mtor, marked improvements were observed in apoptosis, heart function, and survival. Our results demonstrate a role for the MTORC1 signaling network in the myocardial response to stress. In particular, they highlight the role of 4E-BP1 in regulating cardiomyocyte viability and in HF. Because the effects of reduced MTOR activity were mediated through increased 4E-BP1 inhibitory activity, blunting this mechanism may represent a novel therapeutic strategy for improving cardiac function in clinical HF.

Erratum: MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice (Journal of Clinical Investigation (2010) 120, 8, (2805-2816) DOI: 10.1172/JCI43008) / Zhang, D.; Contu, R.; Latronico, M. V. G.; Zhang, J.; Rizzi, R.; Catalucci, D.; Miyamoto, S.; Huang, K.; Ceci, M.; Gu, Y.; Dalton, N. D.; Peterson, K. L.; Guan, K. -L.; Brown, J. H.; Chen, J.; Sonenberg, N.; Condorelli, G.. - In: THE JOURNAL OF CLINICAL INVESTIGATION. - ISSN 0021-9738. - 120:10(2010), p. 3735. [10.1172/JCI43008C1]

Erratum: MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice (Journal of Clinical Investigation (2010) 120, 8, (2805-2816) DOI: 10.1172/JCI43008)

Zhang D.;Rizzi R.;Condorelli G.
2010

Abstract

Mechanistic target of rapamycin (MTOR) plays a critical role in the regulation of cell growth and in the response to energy state changes. Drugs inhibiting MTOR are increasingly used in antineoplastic therapies. Myocardial MTOR activity changes during hypertrophy and heart failure (HF). However, whether MTOR exerts a positive or a negative effect on myocardial function remains to be fully elucidated. Here, we show that ablation of Mtor in the adult mouse myocardium results in a fatal, dilated cardiomyopathy that is characterized by apoptosis, autophagy, altered mitochondrial structure, and accumulation of eukaryotic translation initiation factor 4E–binding protein 1 (4E-BP1). 4E-BP1 is an MTOR-containing multiprotein complex-1 (MTORC1) substrate that inhibits translation initiation. When subjected to pressure overload, Mtor-ablated mice demonstrated an impaired hypertrophic response and accelerated HF progression. When the gene encoding 4E-BP1 was ablated together with Mtor, marked improvements were observed in apoptosis, heart function, and survival. Our results demonstrate a role for the MTORC1 signaling network in the myocardial response to stress. In particular, they highlight the role of 4E-BP1 in regulating cardiomyocyte viability and in HF. Because the effects of reduced MTOR activity were mediated through increased 4E-BP1 inhibitory activity, blunting this mechanism may represent a novel therapeutic strategy for improving cardiac function in clinical HF.
2010
mTORC
01 Pubblicazione su rivista::01a Articolo in rivista
Erratum: MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice (Journal of Clinical Investigation (2010) 120, 8, (2805-2816) DOI: 10.1172/JCI43008) / Zhang, D.; Contu, R.; Latronico, M. V. G.; Zhang, J.; Rizzi, R.; Catalucci, D.; Miyamoto, S.; Huang, K.; Ceci, M.; Gu, Y.; Dalton, N. D.; Peterson, K. L.; Guan, K. -L.; Brown, J. H.; Chen, J.; Sonenberg, N.; Condorelli, G.. - In: THE JOURNAL OF CLINICAL INVESTIGATION. - ISSN 0021-9738. - 120:10(2010), p. 3735. [10.1172/JCI43008C1]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1644820
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 16
social impact